Neuroreport. 2010 Aug 23;21(12):802-7. doi: 10.1097/WNR.0b013e32833ccaf4.
Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease.
Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki J, Toga AW, Beckett L, Green RC, Gamst A, Saykin AJ, Morris J, Potter WZ, Green RC, Montine T, Petersen R, Aisen P, Gamst A, Saykin AJ, Morris J, Potter WZ, Green RC, Montine T, Petersen R, Aisen P, Gamst A, Thomas RG, Donohue M, Walter S, Jack CR Jr, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, Jagust W, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Morris J, Cairns NJ, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee VM, Korecka M, Toga AW, Crawford K, Neu S, Beckett L, Harvey D, Gamst A, Kornak J, Saykin AJ, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Dolen S, Quinn J, Schneider L, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Petersen R, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Tang C, Marzloff G, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert MS, Kozauer N, Zerrate M, Rusinek H, de Leon MJ, De Santi SM, Doraiswamy PM, Petrella JR, Aiello M, Arnold S, Karlawish JH, Wolk D, Smith CD, Given CA 2nd, Hardy P, Lopez OL, Oakley M, Simpson DM, Ismail MS, Brand C, Richard J, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Laubinger MM, Apostolova L, Silverman DH, Lu PH, Graff-Radford NR, Parfitt F, Johnson H, Farlow M, Herring S, Hake AM, van Dyck CH, MacAvoy MG, Benincasa AL, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung GY, Feldman H, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Wu CK, Johnson N, Mesulam M, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Rentz DM, Johnson KA, Rosen A, Tinklenberg J, Ashford W, Sabbagh M, Connor D, Jacobson S, Killiany R, Norbash A, Nair A, Obisesan TO, Jayam-Trouth A, Wang P, Lerner A, Hudson L, Ogrocki P, DeCarli C, Fletcher E, Carmichael O, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Hendin BA, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson G, Blank K, Anderson K, Saykin AJ, Santulli RB, Englert J, Williamson JD, Sink KM, Watkins F, Ott BR, Stopa E, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K.
Source
LIAMA Center for Computational Medicine, National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China.
Abstract
Earlier studies showed that the Val66Met polymorphisms of the brain-derived neurotrophic factor differentially affect gray matter volume and brain region activities. This study used resting positron emission tomography to investigate the relationship between the polymorphisms of Val66Met and the regional cerebral metabolic rate in the brain. We analyzed the positron emission tomography images of 215 patients from the Alzheimer's Disease Neuroimaging Initiative and found significant differences in the parahippocampal gyrus, superior temporal gyrus, prefrontal cortex, and inferior parietal lobule when comparing Met carriers with noncarriers among both the normal controls and those with mild cognitive impairment. For those with Alzheimer's disease, we also found additional differences in the bilateral insula between the carriers and noncarriers.
- PMID:
- 20613678
- [PubMed - indexed for MEDLINE]
- PMCID:
- PMC2954459
Free PMC ArticleFig. 1
The effect of Val66Met polymorphism in clinical disease and normal controls. (a) In the normal control group, reduced cerebral metabolic rate for glucose (CMRglu) was found in the parahippocampal gyrus (right), and the superior temporal gyrus (left) in the Met carriers compared with the noncarriers; in contrast, hyperCMRglu in the superior and prefrontal cortex was found in the Met carriers. (b) In the mild cognitive impairment group, reduced CMRglu in the parahippocampal gyrus (right), insula (right) and superior temporal gyrus (left) was found in the Met carriers; in contrast, hyperCMRglu was found in the middle occipital gyrus (right) and inferior parietal lobule (right) (BA40) in the Met carriers. (c) In the Alzheimer’s disease group, only reduced CMRglu was found in the bilateral insula in the Met carriers compared with the noncarriers.
Neuroreport. 2010 August 23;21(12):802-807.
Publication Types
MeSH Terms
Substances
Grant Support
Full Text Sources
Medical
Molecular Biology Databases